Trends of Gold Nanoparticle-based Drug Delivery System in Cancer Therapy

Journal of Experimental and Clinical Medicine (Taiwan)

Volumn 6, Issue 6, 2014, Pages 172-178

  Ajnai, Giimel ^a   Chiu, Amy ^a   Kan, Tzuchun ^a   Cheng, Chun Chia ^b   Tsai, Teh Hua ^c   Chang, Jungshan ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

Author keywords

Gold nanoparticles; Nanomedicine; Reticuloendothelial system

Indexed keywords

ASPARTIC ACID; CAPECITABINE; CISPLATIN; DOXORUBICIN; GOLD NANOPARTICLE; LIPOSOME; MACROGOL; METHOTREXATE; OXALIPLATIN; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA;

BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CHEMICAL MODIFICATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; HUMAN; LIVER TOXICITY; LUNG CARCINOMA; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OVARY CANCER; REVIEW; SOLID TUMOR; TREND STUDY;

EID: 84916224668     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2014.10.015     Document Type: Review

References (80)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Cho E.C., Glaus C., Chen J., Welch M.J., Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med 2010, 16:561-573.
3. Dreaden E.C., Mackey M.A., Huang X., Kang B., El-Sayed M.A. Beating cancer in multiple ways using nanogold. Chem Soc Rev 2011, 40:3391-3404.
4. Cobley C.M., Chen J., Cho E.C., Wang L.V., Xia Y. Gold nanostructures: a class of multifunctional materials for biomedical applications. Chem Soc Rev 2011, 40:44-56.
5. Libutti S.K., Paciotti G.F., Byrnes A.A., Alexander H.R., Gannon W.E., Walker M., Seidel G.D., et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010, 16:6139-6149.
6. Jatzkewitz H. Incorporation of physiologically-active substances into a colloidal blood plasma substitute. I. Incorporation of mescaline peptide into polyvinylpyrrolidone. Hoppe Seylers Z Physiol Chem 1954, 297:149-156. [in German].
7. Bangham A.D., Horne R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. JMol Biol 1964, 8:660-668.
8. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. JMol Biol 1965, 13:238-252.
9. O'Malley P. Nanopharmacology: for the future-think small. Clin Nurse Spec 2010, 24:123-124.
10. Muthu M.S., Feng S.S. Nanopharmacology of liposomes developed for cancer therapy. Nanomedicine (Lond) 2010, 5:1017-1019.
11. Jain K., Jain N.K. Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discov Today 2013, 18:1272-1281.
12. Jain K., Mehra N.K., Jain N.K. Potentials and emerging trends in nanopharmacology. Curr Opin Pharmacol 2014, 15C:97-106.
13. Rauch J., Kolch W., Laurent S., Mahmoudi M. Big signals from small particles: regulation of cell signaling pathways by nanoparticles. Chem Rev 2013, 113:3391-3406.
14. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
15. Maeda H., Greish K., Fang J. The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century. Adv Polym Sci 2006, 193:103-121.
16. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. JControl Release 2001, 74:47-61.
17. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63:131-135.
18. Haley B., Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008, 26:57-64.
19. Kim D., Jeong Y.Y., Jon S. Adrug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010, 4:3689-3696.
20. Dreaden E.C., Mwakwari S.C., Sodji Q.H., Oyelere A.K., El-Sayed M.A. Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment. Bioconjug Chem 2009, 20:2247-2253.
21. Giljohann D.A., Seferos D.S., Prigodich A.E., Patel P.C., Mirkin C.A. Gene regulation with polyvalent siRNA-nanoparticle conjugates. JAm Chem Soc 2009, 131:2072-2073.
22. Dhar S., Daniel W.L., Giljohann D.A., Mirkin C.A., Lippard S.J. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. JAm Chem Soc 2009, 131:14652-14653.
23. Wang H., Huff T.B., Zweifel D.A., He W., Low P.S., Wei A., Cheng J.X. Invitro and invivo two-photon luminescence imaging of single gold nanorods. Proc Natl Acad Sci U S A 2005, 102:15752-15756.
24. Dreaden E.C., Alkilany A.M., Huang X., Murphy C.J., El-Sayed M.A. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev 2012, 41:2740-2779.
25. Dykman L., Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev 2012, 41:2256-2282.
26. Daniel M.C., Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev 2004, 104:293-346.
27. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. Invivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22:969-976.
28. Tong L., Wei Q., Wei A., Cheng J.X. Gold nanorods as contrast agents for biological imaging: optical properties, surface conjugation and photothermal effects. Photochem Photobiol 2009, 85:21-32.
29. Love J.C., Estroff L.A., Kriebel J.K., Nuzzo R.G., Whitesides G.M. Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 2005, 105:1103-1169.
30. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
31. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
32. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
33. Caliceti P., Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003, 55:1261-1277.
34. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
35. Jin H., Heller D.A., Sharma R., Strano M.S. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano 2009, 3:149-158.
36. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
37. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006, 5. 1909-7.
38. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. JControl Release 2004, 100:247-256.
39. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
40. Dixit V., Van den Bossche J., Sherman D.M., Thompson D.H., Andres R.P. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem 2006, 17:603-609.
41. Low P.S., Antony A.C. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 2004, 56:1055-1058.
42. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. Biomaterials 2009, 30:6065-6075.
43. Chen Y.H., Tsai C.Y., Huang P.Y., Chang M.Y., Cheng P.C., Chou C.H., Chen D.H., et al. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 2007, 4:713-722.
44. Osborne C.K. Tamoxifen in the treatment of breast cancer. NEngl J Med 1998, 339:1609-1618.
45. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004, 25:276-308.
46. Dreaden E.C., Austin L.A., Mackey M.A., El-Sayed M.A. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv 2012, 3:457-478.
47. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009, 9:167-181.
48. Bhattacharyya S., Khan J.A., Curran G.L., Robertson J.D., Bhattacharya R., Mukherjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater 2011, 23:5034-5038.
49. Grandclement C., Borg C. Neuropilins: a new target for cancer therapy. Cancers (Basel) 2011, 3:1899-1928.
50. Bielenberg D.R., Pettaway C.A., Takashima S., Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res 2006, 312:584-593.
51. Kumar A., Huo S., Zhang X., Liu J., Tan A., Li S., Jin S., et al. Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment. ACS Nano 2014, 8:4205-4220.
52. Garg S., De A., Nandi T., Mozumdar S. Synthesis of a smart gold nano-vehicle for liver specific drug delivery. AAPS PharmSciTech 2013, 14:1219-1226.
53. Bergen J.M., von Recum H.A., Goodman T.T., Massey A.P., Pun S.H. Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol Biosci 2006, 6:506-516.
54. Gullotti E., Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 2009, 6:1041-1051.
55. Nativo P., Prior I.A., Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2008, 2:1639-1644.
56. Williams S.C. Spherical nucleic acids: a whole new ball game. Proc Natl Acad Sci U S A 2013, 110:13231-13233.
57. Zheng D., Giljohann D.A., Chen D.L., Massich M.D., Wang X.Q., Iordanov H., Mirkin C.A., et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A 2012, 109:11975-11980.
58. Jayagopal A., Halfpenny K.C., Perez J.W., Wright D.W. Hairpin DNA-functionalized gold colloids for the imaging of mRNA in live cells. JAm Chem Soc 2010, 132:9789-9796.
59. Schaffler M., Sousa F., Wenk A., Sitia L., Hirn S., Schleh C., Harbel N., et al. Blood protein coating of gold nanoparticles as potential tool for organ targeting. Biomaterials 2014, 35:3455-3466.
60. Murawala P., Tirmale A., Shiras A., Prasad B.L. In situ synthesized BSA capped gold nanoparticles: effective carrier of anticancer drug methotrexate to MCF-7 breast cancer cells. Mater Sci Eng C Mater Biol Appl 2014, 34:158-167.
61. Khullar P., Singh V., Mahal A., Dave P.N., Thakur S., Kaur G., Singh J., et al. Bovine serum albumin bioconjugated gold nanoparticles: synthesis, hemolysis, and cytotoxicity toward cancer cell lines. JPhys Chemistry C 2012, 116:8834-8843.
62. Brown S.D., Nativo P., Smith J., Stirling D., Edwards P., Venugopal B., Flint D., et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. JAm Chem Soc 2010, 132:4678-4684.
63. Weintraub K. Biomedicine: The new gold standard. Nature 2013, 495:S14-S16.
64. Riehle K.J., Dan Y.Y., Campbell J.S., Fausto N. New concepts in liver regeneration. JGastroenterol Hepatol 2011, 26:203-212.
65. Tomuleasa C., Soritau O., Orza A., Dudea M., Petrushev B., Mosteanu O., Susman S., et al. Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. JGastrointestin Liver Dis 2012, 21:187-196.
66. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
67. Lee S.M., Kim H.J., Kim S.Y., Kwon M.K., Kim S., Cho A., Yun M., et al. Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer. Biomaterials 2014, 35:2272-2282.
68. Caldorera-Moore M., Guimard N., Shi L., Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010, 7:479-495.
69. Yoo J.W., Doshi N., Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev 2011, 63:1247-1256.
70. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of invitro and invivo studies. Chem Soc Rev 2011, 40:1647-1671.
71. Hirn S., Semmler-Behnke M., Schleh C., Wenk A., Lipka J., Schäffler M., et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011, 77:407-416.
72. Kim K.T., Zaikova T., Hutchison J.E., Tanguay R.L. Gold nanoparticles disrupt zebrafish eye development and pigmentation. Toxicol Sci 2013, 133:275-288.
73. Hwang J.H., Kim S.J., Kim Y.H., Noh J.R., Gang G.T., Chung B.H., Song N.W., et al. Susceptibility to gold nanoparticle-induced hepatotoxicity is enhanced in a mouse model of nonalcoholic steatohepatitis. Toxicology 2012, 294:27-35.
74. De Jong W.H., Hagens W.I., Krystek P., Burger M.C., Sips A.J., Geertsma R.E. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29:1912-1919.
75. Pan Y., Neuss S., Leifert A., Fischler M., Wen F., Simon U., Schmid G., et al. Size-dependent cytotoxicity of gold nanoparticles. Small 2007, 3:1941-1949.
76. Sadauskas E., Jacobsen N.R., Danscher G., Stoltenberg M., Vogel U., Larsen A., Kreyling W., et al. Biodistribution of gold nanoparticles in mouse lung following intratracheal instillation. Chem Cent J 2009, 3:16.
77. Gosens I., Post J.A., de la Fonteyne L.J., Jansen E.H., Geus J.W., Cassee F.R., de Jong W.H., et al. Impact of agglomeration state of nano- and submicron sized gold particles on pulmonary inflammation. Part Fibre Toxicol 2010, 7:37.
78. Schulz M., Ma-Hock L., Brill S., Strauss V., Treumann S., Gröters S., van Ravenzwaay B., et al. Investigation on the genotoxicity of different sizes of gold nanoparticles administered to the lungs of rats. Mutat Res 2012, 745:51-57.
79. Niidome T., Yamagata M., Okamoto Y., Akiyama Y., Takahashi H., Kawano T., Kataymaa Y., et al. PEG-modified gold nanorods with a stealth character for invivo applications. JControl Release 2006, 114:343-347.
80. Simpson C.A., Salleng K.J., Cliffel D.E., Feldheim D.L. Invivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomedicine 2013, 9:257-263.